Metformin Compassionate Use and Expanded Access: How to Get It When Cost or Coverage Is a Barrier

What "Compassionate Use" and "Expanded Access" Actually Mean for Metformin

Compassionate use is a colloquial term for the FDA's formal expanded-access program, which allows patients to receive investigational or unapproved drugs outside of clinical trials when no comparable alternative exists [1]. Metformin received full FDA approval in 1994 and has been off-patent for decades, so the classical expanded-access framework almost never applies to it directly. The access challenges patients face are about cost, coverage, and off-label use, not regulatory status.

The FDA Expanded-Access Framework

Under 21 CFR Part 312 Subpart I, the FDA distinguishes three tiers of expanded access: individual patient access, intermediate-size population access, and widespread treatment protocols [1]. For a generic drug like metformin, none of these pathways are the right tool. A physician submitting an individual-patient IND for metformin would face immediate FDA pushback because approved generics with established safety profiles are excluded from the program's intent [2].

The FDA's own guidance document on expanded access states that the program is designed for "serious or life-threatening conditions" where "no comparable or satisfactory alternative therapy" is available [1]. Metformin at $4 per month at Walmart, Kroger, or Costco Pharmacy does not meet that threshold.

When Expanded Access Might Apply to Metformin-Adjacent Situations

There is one scenario where a metformin-related expanded-access request could be legitimate: a patient enrolled in the TAME trial (Targeting Aging with Metformin, NCT03976648) or a similar longevity-focused investigational protocol who cannot continue participation due to geography or insurance loss [3]. In that context, the principal investigator, not the patient, would initiate expanded access through the trial sponsor. Patients in this situation should contact their trial coordinator directly.

The Real Cost of Metformin in 2026

Generic metformin is one of the least expensive prescription drugs in the United States. The price floor established by Walmart's $4 generics program in 2006 still holds in 2026 for the 500 mg and 850 mg immediate-release tablets. Understanding the actual price field helps patients avoid overpaying.

Immediate-Release vs. Extended-Release Pricing

Metformin immediate-release (IR) 500 mg and 850 mg tablets are the cheapest forms. Metformin extended-release (ER/XR), sold under the brand name Glucophage XR, costs significantly more if purchased as brand-name. Generic ER versions are available but may run $15, $30 per month depending on pharmacy and dose, compared to $4, $10 for IR formulations [4].

The FDA recalled several extended-release metformin products in 2020 due to elevated N-nitrosodimethylamine (NDMA) levels, which temporarily disrupted the ER generic supply [5]. As of 2026, multiple manufacturers have returned compliant ER formulations to market, and the FDA's NDMA monitoring program continues to test metformin products [5].

Discount Card Programs

GoodRx, RxSaver, NeedyMeds, and the manufacturer coupon aggregator Blink Health all list metformin prices below retail. GoodRx prices for metformin 500 mg (60 tablets) ranged from $9 to $14 at CVS, Walgreens, and Rite Aid in 2025 [4]. Costco Pharmacy and Sam's Club Pharmacy routinely price metformin at $4, $5 without a membership discount requirement for prescriptions.

Patients should compare GoodRx prices against their insurance copay before filling. For many patients with high-deductible plans, the GoodRx cash price is lower than the in-network insurance price before the deductible is met [4].

State Pharmaceutical Assistance Programs

Seventeen states operate their own pharmaceutical assistance programs (SPAPs) that cover metformin for uninsured or underinsured residents [6]. California's Medi-Cal covers metformin at zero copay for eligible enrollees. New York's EPIC program covers metformin for seniors not yet eligible for Medicare Part D [6]. The National Council on Aging maintains a BenefitsCheckUp tool at benefits.gov that maps state-specific programs to patient eligibility criteria.

Patient Assistance Programs for Metformin

Because metformin is generic, brand-name manufacturer patient assistance programs (PAPs) do not apply. Novo Nordisk, AstraZeneca, and Merck do not operate PAPs for metformin. The access infrastructure for this drug runs through a different set of organizations.

NeedyMeds and RxAssist

NeedyMeds (needymeds.org) maintains a free database of assistance programs for generic drugs, including metformin. Their metformin listing includes state Medicaid expansion pathways, federally qualified health center (FQHC) resources, and 340B-eligible pharmacy networks [7]. RxAssist (rxassist.org) provides a parallel directory with similar coverage.

Federally Qualified Health Centers (FQHCs)

FQHCs are required by Section 330 of the Public Health Service Act to provide care on a sliding-fee scale regardless of ability to pay [7]. They participate in the 340B Drug Pricing Program, which allows them to purchase outpatient drugs, including metformin, at significantly reduced costs and pass those savings to patients [8]. The Health Resources and Services Administration (HRSA) reported 1,400 FQHC grantees operating over 14,000 service delivery sites as of 2024 [8]. Patients can find their nearest FQHC using the HRSA Find a Health Center tool at findahealthcenter.hrsa.gov.

340B Program Access

The 340B program, administered by HRSA, requires drug manufacturers to provide outpatient drugs to eligible covered entities at a ceiling price that averages 20 to 50% below Medicaid reimbursement rates [8]. For metformin, which already has a low baseline price, 340B pricing may bring the cost to pennies per tablet for facilities enrolled in the program. Patients do not apply to 340B directly; the benefit flows through the health system or pharmacy where they receive care [8].

Metformin for Off-Label Indications: Access and Coverage Hurdles

Metformin's approved indication is type 2 diabetes mellitus in adults and children ages 10 and older [9]. Physicians prescribe it off-label for polycystic ovary syndrome (PCOS), prediabetes, gestational diabetes management, antipsychotic-induced weight gain, and, increasingly, as an anti-aging agent in research contexts. Insurance coverage for off-label use is inconsistent, and this is where most modern access barriers arise.

PCOS and Metformin Coverage

The American Society for Reproductive Medicine (ASRM) practice committee opinion supports metformin use in PCOS for ovulation induction and metabolic management [10]. Despite this professional endorsement, many commercial insurers classify metformin for PCOS as off-label and require prior authorization or step therapy through an oral contraceptive first [10]. Patients facing denial for PCOS indications should ask their prescriber to submit a prior authorization citing the ASRM guideline and ICD-10 code E28.2 (polycystic ovarian syndrome).

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 194 also acknowledges metformin as an option for ovulation induction in PCOS [11]. Citing two professional society guidelines simultaneously strengthens a prior authorization appeal.

Prediabetes and Metformin Coverage

The American Diabetes Association (ADA) 2025 Standards of Care recommend metformin for high-risk prediabetes patients (those with BMI <35, age <60, or a history of gestational diabetes) who do not achieve glycemic targets through lifestyle intervention alone [12]. The recommendation carries a Grade A evidence rating for patients with prior gestational diabetes and Grade B for other high-risk groups [12].

Despite this ADA guidance, Medicare Part D does not cover metformin for prediabetes because the drug lacks an FDA-approved indication for that condition [9]. Commercial insurer coverage varies. Patients paying cash for prediabetes-indicated metformin should use a GoodRx or NeedyMeds coupon, as the cost is low enough that prior authorization battles may not be worth the administrative effort.

Anti-Aging and Longevity Use

The TAME trial (NCT03976648), funded by the American Federation for Aging Research (AFAR), is the first randomized controlled trial designed to test whether metformin delays age-related diseases as a composite endpoint [3]. TAME enrolled 3,000 participants aged 65 to 79 at 14 academic sites across the United States. Results are expected in 2026 or 2027 [3].

Patients outside the trial who want metformin for longevity purposes can obtain it through a physician prescription, but no insurance will cover it for this indication. The cash cost remains low enough that coverage is not the binding constraint. The binding constraint is finding a physician willing to prescribe off-label without a diabetes or PCOS diagnosis on file.

The HealthRX clinical team uses the following three-step access framework for patients requesting metformin outside its approved indication:

1. Confirm no contraindications exist: eGFR <30 mL/min/1.73m², active hepatic disease, or conditions predisposing to lactic acidosis [9].
2. Document the clinical rationale in the chart with a supporting guideline or trial citation.
3. Direct the patient to the lowest-cost cash pathway (FQHC, GoodRx, or Walmart $4 program) rather than triggering an insurance prior authorization that is likely to fail.

HSA and FSA Eligibility for Metformin

Metformin purchased with a valid prescription qualifies as an HSA/FSA-eligible medical expense under IRS Publication 502, which defines qualified medical expenses to include "amounts paid for prescription drugs" [13]. This applies whether the prescription is for an approved indication or an off-label use, as long as the prescription itself is valid.

How to Use HSA/FSA for Metformin

Patients can pay for metformin directly at the pharmacy counter using their HSA debit card. If the card is declined (rare, but possible if the pharmacy's drug classification system does not flag metformin as prescription-eligible), patients can pay out of pocket and submit a reimbursement claim with the pharmacy receipt and prescription label as documentation [13].

Over-the-counter metformin does not exist in the United States; it requires a prescription, which automatically satisfies the IRS requirement for HSA/FSA qualification [9]. Patients should keep pharmacy receipts for a minimum of three years in case of an IRS audit of their HSA account [13].

Contribution Limits for 2026

The IRS set the 2026 HSA contribution limit at $4,300 for self-only coverage and $8,550 for family coverage under a high-deductible health plan (HDHP) [13]. Given that a full year of metformin at the cash price runs $48, $120, HSA funds are more than sufficient to cover it, with room for other medical expenses.

Lactic Acidosis Risk and Access in High-Risk Populations

One underappreciated access issue: patients with chronic kidney disease (CKD) are sometimes denied metformin due to outdated prescribing restrictions, even when their renal function is within acceptable range.

Updated FDA Labeling on Renal Function

The FDA updated the metformin labeling in April 2016 to replace the serum creatinine threshold with an eGFR-based contraindication [9]. The current label contraindicates metformin when eGFR falls below 30 mL/min/1.73m² and recommends reassessment when eGFR is 30 to 45 mL/min/1.73m² [9]. Patients with eGFR >45 mL/min/1.73m² may continue metformin without dose reduction in most cases.

A 2014 Cochrane systematic review of 347 trials found no cases of lactic acidosis attributable to metformin, suggesting the historical restriction for mild-to-moderate CKD was overly conservative [14]. The review concluded that "metformin treatment was not associated with increased risk of lactic acidosis compared with other antihyperglycemic treatments" [14]. This finding contributed to the 2016 FDA labeling change.

Pharmacists at some chains still apply the outdated serum creatinine thresholds. Patients whose prescriptions are flagged should ask the pharmacist to review the current FDA label language, which is available at accessdata.fda.gov [9].

Contrast Media and Temporary Discontinuation

Patients undergoing iodinated contrast procedures are commonly told to hold metformin for 48 hours before and after the procedure due to the risk of contrast-induced nephropathy leading to metformin accumulation [15]. The American College of Radiology (ACR) 2023 Manual on Contrast Media recommends individualized assessment: patients with eGFR >30 mL/min/1.73m² and no acute kidney injury risk factors may not need to hold metformin at all [15]. Blanket discontinuation orders for contrast procedures create unnecessary access gaps and should be reviewed against current ACR guidance.

Metformin in Pregnancy: A Special Access Case

Metformin is classified as Pregnancy Category B (pre-2015 labeling system) and is used off-label for gestational diabetes when insulin is not available or acceptable to the patient [11]. ACOG Practice Bulletin 190 on gestational diabetes states that metformin is an "acceptable alternative" to insulin in certain clinical situations, though placental transfer is documented [11].

Coverage for Gestational Diabetes

Medicaid covers metformin for gestational diabetes in all 50 states, as gestational diabetes is a pregnancy complication covered under mandatory Medicaid maternity benefits [6]. Commercial insurance coverage is similarly broad for this indication given the ACOG endorsement. The access barrier in pregnancy is more often a prescriber comfort issue than an insurance issue.

A 2008 randomized trial published in the New England Journal of Medicine (the MiG trial, N=751) found that neonatal outcomes with metformin were non-inferior to insulin for gestational diabetes, with a lower rate of neonatal hypoglycemia (3.3% vs. 8.1%, P<0.001) [16]. The MiG trial authors noted that "women preferred metformin to insulin," which is a clinically relevant access consideration when insulin administration is a barrier [16].

The UKPDS Evidence Base: Why Access Matters

The United Kingdom Prospective Diabetes Study (UKPDS 34, N=1,704), published in The Lancet in 1998, remains the foundational trial for metformin's cardiovascular and mortality benefits [17]. In the overweight subgroup assigned to metformin, all-cause mortality was reduced by 36% compared to conventional diet therapy (P=0.011), and myocardial infarction was reduced by 39% (P=0.010) [17].

The UKPDS authors wrote that "metformin may be the first-line pharmacological treatment in overweight type 2 diabetic patients," a recommendation now codified in the ADA 2025 Standards of Care and the American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Diabetes Algorithm [12] [18].

When patients lack access to a $4-per-month drug with a 36% mortality reduction, the clinical consequence is not abstract. Rates of diabetes-related emergency department visits are higher among uninsured and underinsured patients [6]. Programs like FQHCs, 340B pricing, and state pharmaceutical assistance programs exist precisely because the downstream cost of untreated diabetes far exceeds the cost of the drug itself.

Practical Step-by-Step Access Pathways

The following pathways are arranged in order of effort required, starting with the lowest barrier.

Pathway 1: Walmart, Kroger, or Costco $4 Program

Walk in with a prescription. Pay $4 for a 30-day supply of metformin IR 500 mg or 850 mg. No insurance required, no prior authorization, no discount card needed. Walmart's list of $4 generics is published at walmart.com/pharmacy [4].

Pathway 2: GoodRx or RxSaver Coupon

Print or pull up the coupon on a smartphone. Present it at any major chain pharmacy. Prices for metformin 500 mg (60 tablets) typically fall between $9 and $14 [4]. GoodRx prices are updated in near-real-time and may be lower than Pathway 1 at specific pharmacies depending on the week.

Pathway 3: FQHC Sliding-Fee Scale

Locate the nearest FQHC at findahealthcenter.hrsa.gov. Schedule an appointment. Income verification determines the sliding-fee percentage. Patients below 100% of the federal poverty level may receive prescriptions and medications at zero cost through the 340B program [8].

Pathway 4: State Pharmaceutical Assistance Program

Use BenefitsCheckUp at ncoa.org or benefits.gov to identify state-specific programs. Application timelines vary from two weeks to 60 days. This pathway is most relevant for seniors with a Medicare coverage gap or for patients in states with strong SPAPs [6].

Pathway 5: HSA/FSA Payment

If enrolled in a high-deductible health plan, use the HSA debit card at any pharmacy. The prescription requirement for metformin in the United States satisfies the IRS qualification standard automatically [13]. This pathway does not reduce the price but shifts the payment to pre-tax dollars, reducing the effective cost by 22 to 37% depending on the patient's marginal tax rate.